On the Record · ICU Medical
ICU Medical acquisitions, on the record
The businesses ICU Medical bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Pfizer Inc.'s Hospira Infusion Systems businessWord for word“In February 2017, we acquired Pfizer Inc.’s (“Pfizer”) Hospira Infusion Systems (“HIS”) business.” 10-K for 2023 | acquisition | In February 2017 | — |
Pursuit Vascular, Inc.Word for word“In November 2019, we acquired Pursuit Vascular, Inc. (“Pursuit”).” 10-K for 2023 | acquisition | In November 2019 | — |
Smiths Medical 2020 Limited, the holding company of Smiths Group plc's global medical device businessWord for word“The cash consideration for the transaction was $1.9 billion, which was financed with existing cash balances and borrowings under the Credit Agreement.” 10-K for 2023 | acquisition | — | The cash consideration for the transaction was $1.9 billion |
a small foreign infusion systems supplierWord for word“In 2021, we acquired a small foreign infusion systems supplier for approximately $15.4 million.” 10-K for 2023 | acquisition | In 2021 | approximately $15.4 million |
Otsuka Pharmaceutical Factory America, Inc.Word for word“In November 2024, we entered into a purchase agreement with Otsuka Pharmaceutical Factory America, Inc.” 10-K for 2024 | agreed divestiture | In November 2024 | — |
a certain line of infusion products in ChinaWord for word“(3) Relates to the sale of a certain line of infusion products in China.” 10-K for 2024 | divestiture | — | — |
Pfizer Inc.'s Hospira Infusion Systems ("HIS") businessWord for word“In February 2017, we acquired Pfizer Inc.’s (“Pfizer”) Hospira Infusion Systems (“HIS”) business.” 10-K for 2025 | acquisition | February 2017 | — |
IV Solutions business (60% interest sold to Otsuka Pharmaceutical Factory America, Inc.)Word for word“Pursuant to the agreement, we sold 60% of our IV Solutions business to Otsuka Pharmaceutical Factory America, Inc. a Delaware corporation ("OPF") and the Company retained 40 % ownership interest in the business.” 10-K for 2025 | divestiture | — | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $2.6 million | $0 | $0 |
| 2017-12-31 | $162.4 million | $0 | $6.5 million |
| 2018-12-31 | $1.3 million | — | $1.3 million |
| 2019-12-31 | $76.1 million | — | $20 million |
| 2020-12-31 | $0 | — | — |
| 2021-12-31 | $14.5 million | — | $10.6 million |
| 2022-12-31 | $1.84 billion | — | $1.47 billion |
| 2023-12-31 | $0 | $0 | — |
| 2024-12-31 | $0 | $0 | — |
| 2025-12-31 | — | $211.2 million | — |
Deal filings since 2016
- 2022-01-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-01-07 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-09-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-09 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-01-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-10-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from ICU Medical’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.